Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M24-560: Telisotuzumab Adizutecan (ABBV-400) plus bevacizumab vs trifluridine/tipiracil (LONSURF) plus bevacizumab in refractory metastatic colorectal cancer
jRCT2031260052Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Objective Response (OR) by BICR and Overall Survival (OS). Started Jun 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031260052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260052.